Variants on the UBE2L3/YDJC Autoimmune Disease Risk Haplotype Increase UBE2L3 Expression by Modulating CCCTC‐Binding Factor and YY1 Binding

Objective Genetic variants spanning UBE2L3 are associated with increased expression of the UBE2L3‐encoded E2 ubiquitin‐conjugating enzyme H7 (UbcH7), which facilitates activation of proinflammatory NF‐κB signaling and susceptibility to autoimmune diseases. We undertook this study to delineate how ge...

Full description

Saved in:
Bibliographic Details
Published inArthritis & rheumatology (Hoboken, N.J.) Vol. 74; no. 1; pp. 163 - 173
Main Authors Gopalakrishnan, Jaanam, Tessneer, Kandice L., Fu, Yao, Pasula, Satish, Pelikan, Richard C., Kelly, Jennifer A., Wiley, Graham B., Gaffney, Patrick M.
Format Journal Article
LanguageEnglish
Published Boston, USA Wiley Periodicals, Inc 01.01.2022
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN2326-5191
2326-5205
2326-5205
DOI10.1002/art.41925

Cover

Loading…
More Information
Summary:Objective Genetic variants spanning UBE2L3 are associated with increased expression of the UBE2L3‐encoded E2 ubiquitin‐conjugating enzyme H7 (UbcH7), which facilitates activation of proinflammatory NF‐κB signaling and susceptibility to autoimmune diseases. We undertook this study to delineate how genetic variants carried on the UBE2L3/YDJC autoimmune risk haplotype function to drive hypermorphic UBE2L3 expression. Methods We used bioinformatic analyses, electrophoretic mobility shift assays, and luciferase reporter assays to identify and functionally characterize allele‐specific effects of risk variants positioned in chromatin accessible regions of immune cells. Chromatin conformation capture with quantitative polymerase chain reaction (3C‐qPCR), chromatin immunoprecipitation (ChIP)–qPCR, and small interfering RNA (siRNA) knockdown assays were performed on patient‐derived Epstein‐Barr virus–transformed B cells homozygous for the UBE2L3/YDJC nonrisk or risk haplotype to determine if the risk haplotype increases UBE2L3 expression by altering the regulatory chromatin architecture in the region. Results Of the 7 prioritized variants, 5 demonstrated allele‐specific increases in nuclear protein binding affinity and regulatory activity. High‐throughput sequencing of chromosome conformation capture coupled with ChIP (HiChIP) and 3C‐qPCR uncovered a long‐range interaction between the UBE2L3 promoter (rs140490, rs140491, rs11089620) and the downstream YDJC promoter (rs3747093) that was strengthened in the presence of the UBE2L3/YDJC risk haplotype, and correlated with the loss of CCCTC‐binding factor (CTCF) and gain of YY1 binding at the risk alleles. Depleting YY1 by siRNA disrupted the long‐range interaction between the 2 promoters and reduced UBE2L3 expression. Conclusion The UBE2L3/YDJC autoimmune risk haplotype increases UBE2L3 expression through strengthening a YY1‐mediated interaction between the UBE2L3 and YDJC promoters.
Bibliography:Supported by the National Institute of General Medical Sciences, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and the National Institute of Allergy and Infectious Diseases of the NIH (grants R01‐AR‐063124, R01‐AR‐073606, R01‐AR‐056360, P30‐GM‐110766, and U19‐AI‐082714) and by the Presbyterian Health Foundation. The Oklahoma Rheumatic Disease Research Cores Center supplied the Epstein‐Barr virus–transformed B cell lines and is supported by the NIH (grants U54‐GM‐104938, P30‐AR‐073750, and UM1‐AI‐144292).
The content of this publication is solely the responsibility of the authors and does not represent the official views of the NIH or the Presbyterian Health Foundation.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2326-5191
2326-5205
2326-5205
DOI:10.1002/art.41925